OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Nuclear Medicine is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Practicing Medicine in Wartime Ukraine	117
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	110
Serial [ ¹⁸ F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair	107
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	102
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	86
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	83
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	82
Quantitative Spatial Profiling of Antibody Delivery and Target Engagement Using Optically Labeled Antibodies	79
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	76
Diagnostic Performance of [ ¹⁸ F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study	72
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	72
Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies	72
Biochemical Recurrence–Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging	71
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	71
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	70
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	70
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	70
Quantitative Deauville Scoring to Uncover Prognostic Information from ¹⁸F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial	69
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	67
Localized In Vivo Prodrug Activation Using Radionuclides	66
Interspecies Variability in Biodistribution and PET Imaging Performance of [¹⁸F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer	65
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	64
Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024)	64
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	63
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	63

¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	63
Renal Medullary Carcinoma: Utility of [ ¹⁸ F]FDG PET/CT in Evaluating Extent of Disease and Impact on Treatment Management	62
PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [ ⁶⁸ Ga]Ga-PSMA-11 PET/CT–Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Gui	61
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	60
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	60
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	58
Delta-like Ligand 3Directed ²²⁵ Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models	58
Theranostics Explained: A Personalized Approach to Cancer Care	58
The Role of Molecular Imaging in Precision Oncology	57
Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [ ¹⁷⁷ Lu]Lu-PSMA Therapy Injections Through Serial	57
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	57
[ ¹⁷⁷ Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial	57
Artificial Intelligence–Powered Quantification of Flortaucipir PET for Detecting Tau Pathology	56
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	55
¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?	52
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”	52
Challenges with¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice	51
Intrapatient 16α-[¹⁸F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast	51
Widespread Prostate Cancer Osseous Metastases: Negative on ¹⁸ F-Piflufolastat PET but Positive on ¹⁸	50
The Research Post	49
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	49
First-in-Human Study of [¹¹C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain	49
Preclinical Evaluation of ⁶⁴ Cu-LNTH-1363S to Detect Cardiac FAP-Positive Fibroblasts Using PET Imaging	47
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	47
Biodistribution, Safety Profile, and Radiation Dosimetry of [¹⁸F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects	47
Funding Reductions Threaten the Future of Medical Innovation	47
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)	46
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	46
Nanoparticle Diagnostics and Theranostics in the Clinic	46
Diuresis During¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial	46
Dual-Time-Point Posttherapy¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome	45
¹⁶¹Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with¹⁷⁷Lu in Preclinical Models of Ovarian Cancer	44
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses	44
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology	44
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer	43
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer	43
Dual-Tracer Imaging on a Long–Axial-Field-of-View PET: A Proof-of-Principle Study with [¹⁸F]FGln and [¹⁸F]FDG	42
Submillimeter-Resolution PET for High-Sensitivity Mouse Brain Imaging	42
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on¹⁸F-FDG PET/MRI and Machine Learning	42
Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors	42
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection	42
Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer	41
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	41
Malignancy Detection Rates of [ ⁶⁸ Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer	41
An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients	41
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	41
Translation of Intraoperative Molecular Imaging for Clinical Use	41
Brain Metabolic Activity Measured by [ ¹⁸ F]FDG PET/CT Predicts Survival in Patients with Advanced Non–Small Cell Lung Cancer	40
Neuroinflammatory PET in Epilepsy: Prospects for Epileptogenic Zone Localization and Presurgical Planning	40
SNMMI/EANM/ASNC/ACNM Procedure Standard/Practice Guideline for ¹⁸F-Flurpiridaz PET Myocardial Perfusion Imaging and Blood Flow Quantitation	39

An External, Independent Validation of anO-(2-[¹⁸F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma	39
Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins	39
¹⁷⁶Lu Radiation in Long–Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety	39
Green Nuclear Medicine and Radiotheranostics	39
Isolated Occipital Lobe Hypometabolism on [ ¹⁸ F]FDG PET	39
Prospective Multicenter Evaluation of [¹¹C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease	39
Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma	39
Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET	39
Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council	39
Clinical Validation of Deep Learning for Image Restoration of Ultra-Low-Count [¹⁸F]FDG PET for Dementia Diagnostics	38
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice	37
Pretargeted Radioimmunotherapy of Ovarian Cancer with²²⁵Ac and an Internalizing Antibody	37
Molecular Imaging, Radiochemistry, and Environmental Pollutants	37
Evaluating Bone Healing with [¹⁸F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment	37
Progression or Response: New Liver Lesions in a Patient with Responding Hodgkin Lymphoma	37
Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study	37
Tumor Dose–Response Relationship of [¹³¹I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [¹²⁴I]MIBG PET	36
Feasibility of¹⁷⁷Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer	36
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry	36
Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review	36
Comparison of Baseline⁶⁸Ga-FAPI and¹⁸F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibit	36
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins	35
From Architecture to Brain Imaging to Leader of a Major Academic Health System	35
Thyroid Hormone Withdrawal Yields Higher ¹³¹ I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a L	35
Differential Response to ¹⁷⁷ Lu-PSMA-617 in Patients with Tumor Suppressor GeneMutated Metastatic Castration-Resistant Prostate Cancer	34
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for²²³Ra-Based Radiopharmaceutical Therapies	34
First-in-Human Study of [ ²¹¹ At]NaAt as Targeted a-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)	34
Preirradiation of Spheroids with ²²⁵Ac-Trastuzumab Improves Penetration of ²²⁵Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails	34
Influence of Ultra-Low-Dose CT on PET Image Quantification and Visual Assessment	34
Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET	34
Potential of¹⁸⁸Re as an Alternative to¹⁷⁷Lu and Dosimetric Consequences	34
⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study	34
First Safety and Efficacy Data with the Radiohybrid¹⁷⁷Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer	34
CD38-Targeted⁸⁹Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care	34
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy	34
Molecular Imaging in Breast Cancer	34
First-in-Human Evaluation of Site-Specifically Labeled⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer	34
The Imperative for Comparative Studies in Nuclear Medicine: Elevating¹⁷⁷Lu-PSMA-617 in the Treatment Paradigm for mCRPC	33
Diagnostic Potential of Supplemental Static and Dynamic⁶⁸Ga-FAPI-46 PET for Primary¹⁸F-FDG–Negative Pulmonary Lesions	33
BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of ²²⁵ Ac-GPC3 (BAY 3547926) in Patients with Advanc	33
High-Resolution Positronium Lifetime Tomography at Clinical Activity Levels on the PennPET Explorer	33
Efficacy, Safety, Blood Kinetics, and ²¹³Bi Distribution Studies of [²²⁵Ac]Ac-SibuDAB in Prostate Cancer Patients	33
Leading Through Change: Reflections from Jason Lewis	33
Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [ ²²⁵ Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor–Expressing, Well-Differe	33
Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma	33
[⁶⁸Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis	32
Not All Gatekeepers Are Theranostics	32
Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?	32
[ ⁶⁸ Ga]Ga-DOTA-5G PET/CT Detects Brain and Bone Metastases in a Patient with Metastatic Pancreatic Cancer	31
Tau PET Visual Reads: Research and Clinical Applications and Future Directions	31
Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer	31
Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?	31
Identification of (R)-[¹⁸F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development	31
CD70-Targeted [¹⁸F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study	31
Histology-Based Radiomics for [¹⁸F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer	31
High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections	30
Multiorgan Perfusion by PET: Potential Multiple Pathophysiology Interacting with the Heart to Guide Systemic and Cardiac Management	30
The Rise of Molecular Image–Guided Robotic Surgery	30
Utility of PSMA PET/CT After an Initial Negative Scan: Results from a Prospective Multicenter PSMA PET Registry	30
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study	30
Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort	30
Histologic Ex Vivo Validation of the [¹⁸F]SITATE Somatostatin Receptor PET Tracer	30
Quantitative [⁸⁹Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI	30
Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on¹⁸F-FDG PET Patterns in Clinical Alzheimer Disease	29
[ ²²⁵ Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and Kidneys	29
First-in-Human Study of¹⁸F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding	29
MIRD Pamphlet No. 29: MIRDy90—A⁹⁰Y Research Microsphere Dosimetry Tool	29
MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy	29
¹⁶¹Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas	29
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior²²³Ra (RALU Study)	29
Quantitative Brain Amyloid PET	29
Stakeholders of Theranostics	28
Distinguishing Progression from Pseudoprogression in Glioblastoma Using¹⁸F-Fluciclovine PET	28
China’s Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact	28
Amino Acid PET in Neurooncology	28
Utility of⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on⁶⁸Ga-PSMA-11 PET/CT	28
Detecting CXCR4 Expression in Meningioma on⁶⁸Ga-Pentixafor PET/MRI	28
A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy	28
Redefining Nuclear Medicine: “Biodistribution” Should Be the Core Concept	27
Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer	27

Theranostics in Perspective: White Paper	27
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy	27
Perspective on Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery	27
Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy	27
Association of Free-to-Total PSA Ratio and¹⁸F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Si	27
[¹⁸F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy	27
Imaging Efficacy of [¹⁸F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study	27
Summary of the 2024 Update of the North American Guidelines for Pediatric Administered Radiopharmaceutical Activities	27
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas	26
Recent Evidence on Cardiac^99mTc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis	26
Delayed Imaging Improves Lesion Detectability in [^99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer	26
Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to ¹⁷⁷ Lu-DOTATATE in Neuroendocrine Tumors	26
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent	26
^99mTc-MIP-1404 SPECT/CT Companion Diagnostic for¹⁷⁷Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer	26
⁶⁸Ga-FAPI-04 PET/CT in Non–Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression	25
Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RA	25
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET	25
Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy	25
Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination	25
Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [¹⁸F]FDG PET/CT and¹³¹I Posttreatment Scanning	25
⁶⁴Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space	25
A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides	25
Safety, Dosimetry, and Feasibility of [⁶⁸Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer	25
Evaluating Radiotheranostic Targets for Endometrial Cancer	25
AI Disclosure Policies: Are We Rearranging Deck Chairs on the Titanic?	25
Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW	24
Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists	24
Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial	24
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for¹⁶¹Tb Compared with¹⁷⁷Lu with a Higher Dose Response for [¹⁶	24
[⁶⁸Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria	24
Theranostic Digital Twins: An Indispensable Prerequisite for Personalized Cancer Care	24
Automated Total-Body Perfusion Imaging with ¹⁵O-Water PET Using Basis Functions and Organ-Specific Model Selection	24
Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose	24
¹⁸F-AlF-NOTA-Octreotide Outperforms⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study	24
Design, Preclinical Evaluation, and Clinical Translation of⁶⁸Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma	24
MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy	24
SV2A PET Imaging Detects Severity-Dependent Synaptic Changes After Experimental Traumatic Spinal Cord Injury	24
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with¹⁶¹Tb and¹⁷⁷Lu: A Comparative Study	24
Fibroblast Activation ProteinTargeted Radiopharmaceutical Therapy Using ¹⁷⁷ Lu-, ⁹⁰ Y-, and	23
FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders	23
Effect of Acute Hypoxia Exposure on the Availability of A₁Adenosine Receptors and Perfusion in the Human Brain	23
A New Dawn	23
The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?	23
Identification of Aldosterone-Producing Adrenal Adenomas Using [ ⁶⁸ Ga]Ga-Pentixafor PET/CT in an Australian Cohort	23
Advancing Nuclear Medicine at the Multiomics Intersection	23
Advancing Tomorrow’s Cancer Medicines	23
Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with ¹⁷⁷ Lu-PSMA: A Retrospective, Single-Cent	23
Validation of Folate Receptor-a Selectivity of 6 S -5-MethyltetrahydrofolateBased Radioconjugates: A Prerequisite for Therapeutic Application?	23
[ ⁶⁸ Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[ ¹⁸	23
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy	23
Reply: Dosimetry in Radiopharmaceutical Therapy	23
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)	23
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE	22
World Health Assembly Resolution WHA78.13 “Strengthening Medical Imaging Capacity”: Impact on Nuclear Medicine Globally	22
First-in-Human Study of the Carbohydrate Nanoparticle ⁶⁴ Cu-Macrin	22
Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma	22
Jeffrey S. Borer MD (1945–2026)	22
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard	22
PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy	22
Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer	22
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer	22
Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial	22
Evaluation of Mitochondrial Complex 1 Density with [¹⁸F]BCPP-EF in a Murine Model and Individuals with Friedreich Ataxia	22
Immunohistochemical FAP Expression Reflects⁶⁸Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma	22
[ ¹¹ C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study	22
⁶¹Cu-Labeled Radiotracers: Alternative or Choice?	22
Nephron-Level Dosimetry Reveals Increased Absorbed Dose Heterogeneity of ¹⁶¹ Tb- Versus ¹⁷⁷ Lu-DOT	22
Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis	22
First-in-Human Study of¹⁸F-Labeled PET Tracer for Glutamate AMPA Receptor [¹⁸F]K-40: A Derivative of [¹¹C]K-2	22
ChatGPT: Can You Prepare My Patients for [¹⁸F]FDG PET/CT and Explain My Reports?	21
Preclinical Investigation of [²¹²Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model	21
Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a ^99m Tc-Ra	21
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up	21
Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview	21
A Timeline of Multimodality Imaging	21
SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy	21
First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [ ⁶⁸ Ga]G	21
Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy	21
Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy	21
Nuclear Cardiology Surrogate Biomarkers in Clinical Trials	21
a-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer	21
Antihormonal-Treatment Status Affects ⁶⁸ Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer	21
Imaging of the Aging Human Brain	20
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of¹⁸F-FDG PET/CT and Conventional CT Imaging	20
Carotid Artery Image-Derived Blood TimeActivity Curves on the NeuroEXPLORER: Initial Multitracer Validation Against Arterial Sampling	20
Differences in Fibroinflammatory Activity Shown on⁶⁸Ga-FAPI-04 and¹⁸F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease	20
Precision Medicine Is Critical for the Future of Oncology	20
[¹⁷⁷Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement	20
Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic¹⁸F-FDG PET Kinetic Modeling	20
Advancing Clinical Trial Innovation in Pancreatic Cancer	20
The Future of Nuclear Medicine in the United States	20
Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using¹¹C-Acetate PET	20
From Scientist to Analyst to Strategist	20
[¹⁸F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lu	20
2024 SNMMI Highlights Lecture: General Clinical Specialties	20